The results indicated robust expression of CD24 in the neuroblastoma patient sample, comparable to the levels seen in previously sensitive IMR-32 cells, predicting sensitivity to viral killing (as opposed to SK-N-AS cells, whose low expression of CD24 indicated resistance to viral killing). This evidence concerns the gene CD24 and neuroblastoma.